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SDC were $AU37,491 and $AU33,360, respectively, with an in-
cremental cost of $AU4,131. The AUC0-inﬁnity was 6.5 and 3.5
patient life-years, respectively, leading to an incremental beneﬁt of
3.0 life-years gained. This gives an ICER of $AU1,377 per dis-
counted life-year gained. Compared with published studies of IC-
ERs for HDC versus SDC in multiple myeloma and metastatic
breast cancer, these results support HDC as a cost-effective treat-
ment in relapsed aggressive NHL.
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PHASE II TRIAL OF GM-CSF AS MAINTENANCE THERAPY POST–AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
MULTIPLE MYELOMA
Mandanas, R.A., Beveridge, R., Rifkin, R.M., Greenspan, A.R.,
Orloff, G.J., Klein, L.M., Rauch, M.A., Boehm, K.A., Zhan, F.,
Asmar, L. US Oncology Research, Inc., Houston, TX.
Background: It has been hypothesized that GM-CSF may stim-
ulate monocytes and dendritic cells, resulting in an increased im-
mune-mediated recognition and cytotoxic effect against myeloma.
Methods: Forty study subjects, who did not show progression
within the ﬁrst 120 days following their autotransplantations, were
enrolled at 9 sites throughout the US Oncology transplantation
network. The median age was 59.2 years (range, 42.4–78.7 years),
67.5% were male, 32.5% were white, and the PS scores (0/1) were
62.5% and 37.5%, respectively. Participants were instructed on the
proper technique for giving themselves subcutaneous (SC) injec-
tions at their ﬁrst dose visit. Subsequently, subjects self-adminis-
tered 250 g GM-CSF (Leukine, Berlex Laboratories, Seattle,
WA) SC daily for days 1–14 of each 28-day cycle, for a total of 1
year. Nonhematologic toxicities were managed symptomatically if
they were grade 2 (excluding nausea and alopecia); for toxici-
ties  grade 3, the treatment was withheld until the event recov-
ered to  grade 1. For WBC count  20,000/mL or platelet
count  500,000/mL, doses of GM-CSF were reduced by 50% (to
125 g). Results: There were 40 eligible participants. At 1 year
from transplantation, 12 subjects relapsed or died, and the product-
limit estimated progression-free survival rate (PFS) was 65.1% (vs
60% in unpublished data). The 2-year PFS was 50.6% (vs 40% in
unpublished data). The median PFS was 16.3 months (range,
5–25.3 months), and at 2 years, the estimated survival was 84%.
Toxicity was limited. Grade 3 or 4 treatment-related events in-
cluded dyspnea and bone pain (5% each) and myalgia and chest
pain (2.5% each). There were 4 deaths; none were treatment-
related. Conclusions: Administration of GM-CSF posttransplan-
tation for myeloma is feasible and may delay progression of the
disease.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) USING REDUCED
INTENSITY CONDITIONING (RIC) IN THE PATIENTS WITH RECURRENT
AND REFRACTORY MALIGNANT LYMPHOPROLIFERATIVE DISORDERS
Raida, L.1, Faber, E.1, Papajik, T.1, Indrak, K.1, Zapletalova, J.2,
Vitek, A.3, Koza, V.4 1Hemato-oncology Department, University Hos-
pital, Olomouc, Czech Republic; 2Centre of Biomedical Information,
Medical School of Palacky University, Olomouc, Czech Republic; 3Insti-
tute of Hematology and Blood Transfusion, Prague, Czech Republic;
4Hemato-oncology Department, University Hospital, Pilsen, Czech Re-
public.
Background: An evidence of graft versus tumor (GvT) effect
revealed a new therapeutic opportunity for conventionally incur-
able patients suffering from lymphoid malignancies. RIC allows us
to achieve the engraftment of donor immunocompetent cells and
to avoid unnecessary toxicity in usually heavily pretreated patients.
We present a cohort of patients allografted after RIC because of
recurrent/refractory malignant lymphoproliferation. Methods:
Nineteen patients (median age, 50 years; range, 33–68 years) with
recurrent/refractory malignant lymphoproliferations (5 cases of
B-CLL [26%], 12 cases of B-NHL [63%], 2 cases of T-NHL
[11%]) were allografted after ﬂudarabine-based RIC. Fifteen pa-
tients (79%) received SCT from sibling donors; 4 (21%), from
unrelated donors. Cyclosporin-A (CSP) was administered as sin-
gle-agent GvHD prophylaxis in 8 (42%) patients. A combination
with methotrexate (MTX) and mycophenolate mofetil (MMF) was
used in 6 (32%) and 5 (26%) patients, respectively. The immuno-
suppression was gradually tapered and stopped between days 30
and 180 based on the therapeutic response, chimerism, and
GvHD development. The median follow-up is 12 months (range,
1–33 months). Results: Seventeen (90%) recipients achieved com-
plete remission (CR) of disease. After SCT, disease relapse and
progression were observed in 4 (21%) and 2 (11%) patients, re-
spectively. Thirteen (68%) patients developed acute, chronic, or
both forms of GvHD. Nine (48%) recipients died. The causes of
death were disease progression in 3 patients (16%) and transplan-
tation-related complications in 6 patients (32%). Estimated 2-year
event-free survival (EFS) was 30%, and estimated overall survival
(OS) was 47%. Conclusions: Our results conﬁrm the evidence of
GvT reaction and effective tumor control in otherwise incurable
patients treated with allografting after RIC. The major problem
remains GvHD and related complications responsible for signiﬁ-
cant morbidity and mortality.
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SALVAGE THERAPY WITH CDME SCHEDULE FOLLOWED BY PBSC
TRANSPLANTATION IN 20 LYMPHOMA PATIENTS: AN INTENTION-TO-
MOBILIZE AND TRANSPLANTATION ANALYSIS
Won, J.-H., Kim, H.-J., Lee, N.-S., Lee, S.-H., Bae, S.-B.,
Kim, C.-K., Lee, K.-T., Park, S.-K., Hong, D.-S., Park, H.-S. Division
of Hematology-Oncology and Institute for Clinical Molecular Biology
Research, Soon Chun Hyang University College of Medicine, Seoul,
Korea.
The combination of mitoxantrone, etoposide, cisplatin, and
dexamethasone (CDME regimen) is an effective salvage regimen
for lymphoproliferative disease. Our study analyzed this combina-
tion in mobilization of peripheral blood stem cells in patients with
relapsed, refractory, or high-risk lymphoma. The study included
20 patients with non-Hodgkin’s lymphoma (NHL) (17 males and
3 females). The median age was 53 years (range, 18–66 years).
According to the working formulation, there were 13 patients with
intermediate grade, 6 with high grade, and 1 with low grade.
Age-adjusted IPI analysis showed 8 patients with 1 risk factor, 10
with 2 risk factors, and 2 with 3 risk factors. After 2 courses of
CDME, the overall and complete response (CR) rates were 65%
and 30%, respectively. Mobilization was successful in all patients.
The median MNC yield was 7.85  108/kg (range, 3.49–20.12),
and CD34 cell yield was 11  106/kg (range, 2.08–38.7). No
factors affect the mobilization outcome after CDME schedule. All
patients received high-dose chemotherapy and autologous periph-
eral blood stem cell transplantation (PBSCT), and 1 toxicity-
related death occurred. In autografts carried out using CDME-
mobilized PBSC, the median time to neutrophils  500/mm3 was
10 days (range, 1–44 days) and that to platelets  20,000/mm3 was
11 days (range, 2–47 days). The overall response rate was 78.9%
(CR 68.4% and PR 10.5%), and median PFS and OS were 9 and
16 months, respectively, after PBSCT. In multivariate analysis,
ECOG performance status, age-adjusted IPI, and disease status
before transplantation were signiﬁcantly associated with PFS and
OS. Our results demonstrate that the CDME regimen is effective
in refractory or relapsed NHL, resulting in successful stem cell
mobilization.
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GM-CSF AND INTERFERON- MAINTENANCE THERAPY FOR MULTIPLE
MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTA-
TION (ASCT): AN INTERIM REPORT
Gowda, S., Cogle, C.R., Khan, S.A., Moreb, J.S. University of Florida,
College of Medicine, Gainesville, FL.
Maintenance therapy with IFN-	 has been shown to delay mul-
tiple myeloma (MM) relapse with variable effect on overall sur-
vival. In our experience, 30% of patients are unable to effectively
take IFN-	 after ASCT because of IFN-	–induced cytopenias. We
hypothesize that the inclusion of GM-CSF will prevent the my-
elosuppresion by IFN-	 and may further improve the clinical
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